

Amendments to the Specification:

Please replace the paragraph at page 16, line 23 through page 21, line 20, with the following paragraph:

--In further embodiments of formula I, the compound is any one of

- (S)-1-{2-[2-(4-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-{2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-Methoxy-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3,4-Difluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 1-{2(R/S)-[2-(4-Chloro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 1-{2(R/S)-[2-(3,4-Difluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- (S)-1-{2-[2-(3-Fluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 1-{2(R/S)-[2-(3-Fluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 1-{2(R/S)-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 1-{2(R/S)-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- ({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
- 2-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
- ({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid ({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- ({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- {2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-methyl}-piperidin-1-yl)-acetic acid,
- ({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- {4-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,

(N-2-propyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
(N-Ethyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
2-{3-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
(S)-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,
({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
(N-2-propyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,
({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
({2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
{4-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,
2-{3-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-2-propyl-amino)-acetic acid
({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
{2-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenoxy]methyl}-piperidin-1-yl}-acetic acid,
({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
(N-Methyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
2-{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
2-{3(R)-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
2-[3(R)-(2-(4-methylphenyl)-sulfanyl-phenoxy]-pyrrolidin-1-yl}-propionic acid,
(3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,
2-{3(R)-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
2-{3(R)-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]methyl}-propyl)-N-ethyl-amino)-acetic acid,
({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]butan-2-yl}-N-ethyl-amino)-acetic acid ({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]butan-2-yl}-N-ethyl-amino)-acetic acid,
({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]butan-3-methyl-2-yl}-N-ethyl-amino)-acetic acid,
({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]butan-2-yl}-N-ethyl-amino)-acetic acid,
({1-[1-(3-Chloro-phenylsulfanyl)-phenoxy]propan-2-yl}-N-ethyl-amino)-acetic acid,

((1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-4-methyl-2-yl))-N-ethyl-amino)-acetic acid ((1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl)-N-ethyl-amino)-acetic acid,

((1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-ethyl-amino)-acetic acid,

(S)-(1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-methyl-amino)-acetic acid (S)-(1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-methyl-amino)-acetic acid,

(S)((1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-ethyl-amino)-acetic acid (S)-(1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-ethyl-amino)-acetic acid,

((1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-ethyl-amino)-acetic acid,

((1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-ethyl-amino)-acetic acid,

((1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]methyl)-propyl)-N-methyl-amino)-acetic acid,

((1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]methyl)-propyl)-N-ethyl-amino)-acetic acid,

(N-Ethyl-{1-[2-(3-fluoro-phenylsulfanyl)-phenoxy]methyl}-propyl)-amino)-acetic acid,

(R)-(2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-1-methyl-ethyl)-N-ethyl-amino)-acetic acid,

(S)-(2-[2-(4-Chloro-phenoxyl)-phenoxy]propyl-N-methyl-amino)-acetic acid (S)-(2-[2-(4-Chloro-phenoxyl)-phenoxy]propan-2-yl)-N-methyl-amino)-acetic acid,

(R)-(2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]propyl-N-methyl-amino)-acetic acid (R)-(2-[1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]propan-2-yl]-N-methyl-amino)-acetic acid,

((2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]propyl)-N-methyl-amino)-acetic acid,

((2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]propan-1-yl)-N-ethyl-amino)-acetic acid,

((1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl)-N-methyl-amino)-acetic acid,

((3-methyl-1-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]butan-2-yl)-N-ethyl-amino)-acetic acid,

((1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]butan-2-yl)-N-methyl-amino)-acetic acid,

(S)-(1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-methyl-amino)-acetic acid (S)-(1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-methyl-amino)-acetic acid,

(S)-(2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]propyl)-N-methyl-amino)-acetic acid (S)-(2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]propan-2-yl)-N-methyl-amino)-acetic acid,

((1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl)-N-ethyl-amino)-acetic acid,

(S)-({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid,
({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl butan-2-yl}-N-methyl-amino)-
acetic acid ({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-
methyl-amino)-acetic acid,
({1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-propan-2-yl}-N-ethyl-amino)-acetic acid
{1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,
({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-ethyl-amino)-acetic acid,
({2-[2-(4-methoxy-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-Cyclohexyl-amino)-acetic acid,
{[2-(2-(4-methylsulfanyl-phenoxy)-propan-1-yl]-N-cyclohexyl-amino}-acetic acid {[2-(2-(4-
methyl-phenylsulfanyl-phenoxy)-propan-1-yl]-N-cyclohexyl-amino}-acetic acid,
({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-cyclohexyl-amino)-acetic acid,
(S)-1-{3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propyl}-pyrrolidine-2-carboxylic acid,
(S)-2-{(2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-propionic acid,
({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-acetic acid,
(S)-1-{2-[4-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-[2-[3-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl]pyrrolidine-2-carboxylic acid
(S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,
(S)-1-{2-[5-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,
(S)-1-{2-[4-Cyano-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid
(S)-1-{2-[5-Chloro-2-phenylsulfanyl-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,
(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-2-[4'-Methoxy-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-
carboxylic acid,
(S)-{2-[4'-Cyano-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic
acid,
(S)-1-{2-[4'-Cyano-4-(3-fluoro-phenylsulfanyl)-biphenyl-3-yloxy]-ethyl}-pyrrolidine-2-
carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-5-thiophen-3-yl-phenoxy]-ethyl}-pyrrolidine-2-
carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-pyrimidin-5-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-3-methanesulfonyl-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2(S)-carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-morpholin-4-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-piperidin-1-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
or a pharmaceutically acceptable salt thereof. Each of these compounds is considered a specific embodiment and may be subject to individual claims.--

Please replace the paragraph at page 24, line 31 through page 25, line 29, with the following paragraph:

-- In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of Alzheimer's disease. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of multi-infarct dementia. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of AIDS dementia. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of dementia. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of Huntington's disease. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of Parkinson's disease. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of amyotrophic lateral sclerosis. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of diseases wherein the brain is damaged by inner or outer influence. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of trauma to the head. In a further embodiment, the present invention relates to

use of a compound of formula I for the preparation of a medicament for the treatment of stroke. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of convulsive disorders. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of epilepsy. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of spasticity. In a further embodiment, the present invention relates to use of a compound of formula I for the preparation of a medicament for the treatment of myoclonus. In a further embodiment, the present invention relates to the use of a compound of formula I as above or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of post-traumatic stress disorder. The medicament may comprise any one of the embodiments of formula I described above.--

Please replace the paragraph at page 52, lines 20-22, with the following paragraph:

--Iau ((2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]ethyl)-N-methyl-amino)-acetic acid ((2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]ethyl)-N-methyl-amino)-acetic acid
from [(2-Hydroxy-ethyl)-methyl-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 351.9 (MH⁺); RT = 2.02; purity (UV, ELSD): 98%, 100%; yield: 9.9mg

Please replace the paragraph at page 56, lines 23-26, with the following paragraph:

--Ibx ((1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]butan-2-yl)-N-ethyl-amino)-acetic acid ((1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]butan-2-yl)-N-ethyl-amino)-acetic acid
from [Ethyl-(1-hydroxymethyl-propyl)-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 428.1 (MH⁺); RT = 2.46; purity (UV, ELSD): 94%, 100%; yield: 4.6mg--

Please replace the paragraph at page 57, lines 11-14, with the following paragraph:

--Icb ((1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]butan-4-methyl-2-yl)-N-ethyl-amino)-acetic acid ((1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]butan-3-methyl-2-yl)-N-ethyl-amino)-acetic acid
from [Ethyl-(1-hydroxymethyl-2-methyl-propyl)-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 426.2 (MH^+); RT = 2.42; purity (UV, ELSD): 90%, 100%; yield: 0.9mg--

Please replace the paragraph at page 57, lines 21-24, with the following paragraph:

--1cd (S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid
(S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid
from (S)-[(2-Hydroxy-1-methyl-ethyl)-methyl-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 366.2 (MH^+); RT = 2.08; purity (UV, ELSD): 98%, 97%; yield: 4.4mg--

Please replace the paragraph at page 57, lines 26-29, with the following paragraph:

--1ce (S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid
(S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid
from (S)-[Ethyl-(2-hydroxy-1-methyl-ethyl)-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 380.2 (MH^+); RT = 2.18; purity (UV, ELSD): 72%, 100%; yield: 1.3mg--

Please replace the paragraph at page 58, lines 29-31, with the following paragraph:

--1cl (S)-(2-[2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl-N-methyl-amino)-acetic acid (S)-(2-[2-(4-Chloro-phenoxy)-phenoxy]-propan-2-yl)-N-methyl-amino)-acetic acid from (S)-[(2-Hydroxy-1-methyl-ethyl)-methyl-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 350.1 (MH^+); RT = 2.00; purity (UV, ELSD): 96%, 97%; yield: 2.6mg--

Please replace the paragraph at page 59, lines 1-4, with the following paragraph:

--1cm (R)-(2-[2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl-N-methyl-amino)-acetic acid
(R)-(2-[1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl]-N-methyl-amino)-acetic acid
from (R)-[(2-Hydroxy-1-methyl-ethyl)-methyl-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 366.1 (MH^+); RT = 2.10; purity (UV, ELSD): 98%, 98%; yield: 6.1mg--

Please replace the paragraph at page 59, lines 31-33, with the following paragraph:

--1cs (S)-(1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl)-N-methyl-amino)-
acetic acid (S)-(1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl)-N-methyl-
amino)-acetic acid

from (S)-[(2-Hydroxy-1-methyl-ethyl)-methyl-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 384.1 (MH⁺); RT = 2.16; purity (UV, ELSD): 97%, 100%; yield: 3.7mg--

Please replace the paragraph at page 60, lines 1-4, with the following paragraph:

--1ct (S)-[2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl]-N-methyl-amino)-acetic acid (S)-[1-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl]-N-methyl-amino)-acetic acid

from (S)-[(2-Hydroxy-1-methyl-ethyl)-methyl-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 350.1 (MH⁺); RT = 1.97; purity (UV, ELSD): 91%, 97%; yield: 5.5mg--

Please replace the paragraph at page 60, lines 16-19, with the following paragraph:

--1cw ([1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl]-N-methyl-amino)-acetic acid ([1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl]-N-methyl-amino)-acetic acid

from [(1-Hydroxymethyl-2-methyl-propyl)-methyl-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 412.0 (MH⁺); RT = 2.35; purity (UV, ELSD): 87%, 97%; yield: 3.0mg--

Please replace the paragraph at page 60, lines 21-24, with the following paragraph:

--1cx ([1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-propan-2-yl]-N-ethyl-amino)-acetic acid ([1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-propan-2-yl]-N-ethyl-amino)-acetic acid

from [Ethyl-(2-hydroxy-1-methyl-ethyl)-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 402.2 (MH⁺); RT = 2.53; purity (UV, ELSD): 90%, 99%; yield: 3.4mg--

Please replace the paragraph at page 61, lines 3-6, with the following paragraph:

*--1da {[2-(2-(4-methylsulfanyl-phenoxy)-propan-1-yl)-N-cyclohexyl-amino]-acetic acid
{[2-(2-(4-methyl-phenylsulfanyl-phenoxy)-propan-1-yl)-N-cyclohexyl-amino]-acetic acid}*

from [Cyclohexyl-(2-hydroxy-propyl)-amino]-acetic acid tert-butyl ester

LC/MS (m/z) 414.4 (MH⁺); RT = 2.50; purity (UV, ELSD): 79%, 100%; yield: 1.1mg--

Please replace the paragraph at page 63, lines 24-27, with the following paragraph:

--3b (S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfonyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid hydrochloride (S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfonyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid hydrochloride

from of 3-Chloro-2-(3-fluoro-phenylsulfonyl)-phenol

Yield 452mg--